Full-Year Data Back TYK2 Blocker in Psoriatic Arthritis

(MedPage Today) — CHICAGO — Deucravacitinib (Sotyktu), a plaque psoriasis drug, now appears likely to win an indication for psoriatic arthritis (PsA) in the near future, with 1-year results reported here from one of its key Phase III trials. Further away…